- Home
- CLW vs ANNX Comparison
CLW vs ANNX Comparison
Compare CLW & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- ANNX
- Stock Information
- Founded
- CLW 2005
- ANNX 2011
- Country
- CLW United States
- ANNX United States
- Employees
- CLW N/A
- ANNX N/A
- Industry
- CLW Paper
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- CLW Basic Materials
- ANNX Health Care
- Exchange
- CLW Nasdaq
- ANNX Nasdaq
- Market Cap
- CLW 293.0M
- ANNX 334.1M
- IPO Year
- CLW N/A
- ANNX 2020
- Fundamental
- Price
- CLW $17.41
- ANNX $4.28
- Analyst Decision
- CLW Strong Buy
- ANNX Strong Buy
- Analyst Count
- CLW 2
- ANNX 4
- Target Price
- CLW $30.00
- ANNX $16.50
- AVG Volume (30 Days)
- CLW 211.8K
- ANNX 3.0M
- Earning Date
- CLW 10-28-2025
- ANNX 11-10-2025
- Dividend Yield
- CLW N/A
- ANNX N/A
- EPS Growth
- CLW 875.72
- ANNX N/A
- EPS
- CLW 8.63
- ANNX N/A
- Revenue
- CLW $1,556,100,000.00
- ANNX N/A
- Revenue This Year
- CLW $13.91
- ANNX N/A
- Revenue Next Year
- CLW N/A
- ANNX N/A
- P/E Ratio
- CLW $2.00
- ANNX N/A
- Revenue Growth
- CLW 23.00
- ANNX N/A
- 52 Week Low
- CLW $16.53
- ANNX $1.29
- 52 Week High
- CLW $33.57
- ANNX $5.66
- Technical
- Relative Strength Index (RSI)
- CLW 38.35
- ANNX 73.64
- Support Level
- CLW $17.68
- ANNX $2.54
- Resistance Level
- CLW $18.84
- ANNX $5.07
- Average True Range (ATR)
- CLW 0.68
- ANNX 0.31
- MACD
- CLW -0.06
- ANNX 0.14
- Stochastic Oscillator
- CLW 33.96
- ANNX 68.18
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.